

Rapid Case Review: Investigators Provide Perspectives on Actual Cases of Urothelial Metastatic Bladder Cancer — Issue 6

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following adverse events is commonly associated with enfortumab vedotin?
 - a. Constipation
 - b. Hyperglycemia
 - c. Atrial fibrillation
2. Which of the following drug types best describes the mechanism of action of erdafitinib?
 - a. VEGF inhibitor
 - b. PD-L1 inhibitor
 - c. FGFR tyrosine kinase inhibitor
3. Which of the following adverse events is commonly associated with erdafitinib?
 - a. Hyperphosphatemia
 - b. Gastrointestinal dysfunction
 - c. Nail changes
 - d. All the above
4. Which of the following statements is correct regarding drug-induced pneumonitis in a patient receiving front-line combination therapy with enfortumab vedotin and pembrolizumab for metastatic urothelial bladder cancer?
 - a. The pneumonitis is exclusively attributable to the immune-mediated mechanisms of pembrolizumab
 - b. The pneumonitis is exclusively attributable to the cytotoxic payload or off-target effects of enfortumab vedotin
 - c. Both enfortumab vedotin and pembrolizumab can independently induce pneumonitis